News
GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...
Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...
A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...
Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...
The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.
GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...
A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA ...
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...
A report from the human resources trade group SHRM, which just released its 2025 Benefits Survey—the most comprehensive ...
According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results